Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 196.51M P/E - EPS this Y - Ern Qtrly Grth -
Income -28.89M Forward P/E - EPS next Y - 50D Avg Chg -10.00%
Sales 34.48M PEG - EPS past 5Y - 200D Avg Chg -10.00%
Dividend N/A Price/Book 1.93 EPS next 5Y - 52W High Chg -27.00%
Recommedations - Quick Ratio 2.87 Shares Outstanding 49.86M 52W Low Chg 12.00%
Insider Own - ROA -9.91% Shares Float 41.80M Beta 0.87
Inst Own 1.30% ROE -35.57% Shares Shorted/Prior 95.19K/98.94K Price 3.67
Gross Margin 100.00% Profit Margin -83.79% Avg. Volume 106,853 Target Price -
Oper. Margin -56.31% Earnings Date Apr 4 Volume 17,947 Change 2.23%
About GENFIT S.A.

Genfit S.A., a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. The company was incorporated in 1999 and is headquartered in Loos, France.

GENFIT S.A. News
04/25/24 GENFIT: Publication of the 2024 Extra-Financial Performance Report (fiscal year 2023)
04/15/24 GENFIT Annual Combined General Meeting of May 22, 2024 — Availability of Preparatory Documents
04/05/24 GENFIT Announces Publication of the 2023 Universal Registration Document and the 2023 Annual Report on Form 20-F
03:10 PM GENFIT Reports Full-Year 2023 Financial Results and Provides Corporate Update
02/29/24 GENFIT Announces Revenues and Cash Position as of December 31, 2023
01/15/24 GENFIT Announces 2024 Financial Calendar
01/11/24 GENFIT: Half-Year Report of Liquidity Contract with Crédit Industriel et Commercial
12/08/23 GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)
12/07/23 Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC
12/06/23 GENFIT Announces Publication in the Journal of Hepatology on the Accurate Performance of NIS2+™ as a Screening Tool for the Enrollment of Patients in MASH Clinical Trials
11/16/23 GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023
11/13/23 GENFIT: Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine
11/09/23 GENFIT Reports Third Quarter 2023 Financial Information
11/02/23 GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023
09/26/23 GENFIT Announces Publication in Nature Medicine Confirming the Performance of its NASH Diagnostic Technology
09/26/23 GENFIT S.A. Unsponsored ADR (GNFT) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
09/20/23 GENFIT Reports First Half-Year 2023 Financial Results and Provides Corporate Update
09/05/23 GENFIT to Participate in Upcoming Investor Conferences
08/10/23 GENFIT Announces the Publication of New Data on the Clinical Performance of NIS2+™ in Older Patients in Hepatology Communications
06/30/23 Ipsen, Genfit's Elafibranor Shows Promise In Primary Biliary Cholangitis Patients
GNFT Chatroom

User Image badhombre88 Posted - 04/25/24

$GNFT 12k brazy vol and 50% more than 10 day avg vol

User Image RallyRaider Posted - 04/22/24

$GNFT sign of life?

User Image badhombre88 Posted - 04/22/24

$GNFT 8k brazy vol and 50% more than 10 day avg vol

User Image GrizzliesTwits Posted - 04/08/24

@buymoremakemore @CliffordCapital @DebWater_ $GNFT have no volume…

User Image buymoremakemore Posted - 04/07/24

@CliffordCapital @DebWater_ After $xfor thinking of doing $GNFT PDUFA in June, then $ADAP PDUFA in August then $DERM PDUFA i in November

User Image OpenOutcrier Posted - 4 weeks ago

Top Earnings Th 4/4 Aft: $GNFT $KRUS . Top Earnings Fri 4/5 Pre: $BYRN $GBX

User Image RallyRaider Posted - 1 month ago

$GNFT bot 1k shares, i think is in for a treat

User Image RallyRaider Posted - 1 month ago

$GNFT very quiet here.... almost as quiet as the company itself. 300 shares traded in a session

User Image UraniumFox Posted - 03/27/24

$GNFT adding on weakness going into FDA in November

User Image RallyRaider Posted - 02/21/24

$GNFT ppar compare mcap CBAY GNFT, you get their other stuff on top --------do the thing now silly!

User Image tradethehalt Posted - 02/19/24

Mid-Day Top 5 Gainers Report: $GNFT (0%) $SHUS (0%) $BFAM (0%) $ZBRA (0%) $OMC (0%) If we missed a split/reverse split, let us know!

User Image JerrieGauze Posted - 02/14/24

$GNFT hey toni glad about ur excitement in phase 2 call my secretary when phase three is revealed in q whatever ……

User Image Toni19 Posted - 02/13/24

$AUPH Sorry to the AUPH board here, because i show up here with HEPA! But i must say, if this company HEPA or Hepion is in the right hands, i think, this drug is a future blockbuster drug! Just saying! Like everybody know, bevor Foster comeback to Aurinia again, he was the CEO of Hepion! It is good possible, that AUPH take over HEPA for a small price! Some say here on this board, 20 million dollar, or less! I mean, that is nothing for a molecule, like this from HEPA or Hepion for NASH! Right? @BioAmerica It is a different plan, i know! If i have a choice, i prefer a bo by Otsuka, GSK, or who ever! 2024 we are cash flow positiv! So, i am very interested, where Aurinia going, on the end! If i look the BOD from AUPH, all have a very nice background! Thanks to @5xStarTrader for uploading this stuff and thanks to @US_Bull for your new investment idea for $GNFT I will make my DD! Who knows, maybe $GNFT is a winner! 👍👊😏

User Image US_Bull Posted - 02/12/24

$GNFT Started a position will add on any weakness I like their struucture and partnership with Ipsen and breakthrough status average around 3.93$.

User Image Stocks4thought Posted - 02/12/24

$GNFT LSD https://www.cnbc.com/2024/02/12/drugmaker-gilead-to-acquire-cymabay-for-4point3-billion.html

User Image US_Bull Posted - 02/12/24

$GNFT So ICPT and CBAY BO GNFT next ?

User Image morningmover Posted - 01/26/24

$GNFT this should do well this year

User Image Stocks4thought Posted - 01/24/24

$GNFT Super$

User Image Stocks4thought Posted - 01/23/24

$GNFT Smoking$

User Image TrendyChart Posted - 01/23/24

$GNFT The stock chart navigates through resistance like a seasoned captain, guided by the compass of strong technical indicators and a path towards prosperity. 📊 https://thetrendychart.com/

User Image RallyRaider Posted - 01/23/24

$GNFT is just Seladelpar on sale?

User Image RallyRaider Posted - 01/22/24

$GNFT on close watch

User Image risenhoover Posted - 01/17/24

$GNFT / Genfit S.A. - Depositary Receipt () files form 6-K https://fintel.io/doc/sec-genfit-sa-1757064-6k-2024-january-17-19739-4778?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image STCKPRO Posted - 01/15/24

$GNFT NEW ARTICLE : GENFIT Announces 2024 Financial Calendar https://www.stck.pro/news/GNFT/72790803/

User Image risenhoover Posted - 01/11/24

$GNFT / Genfit S.A. - Depositary Receipt () files form 6-K https://fintel.io/doc/sec-genfit-sa-1757064-6k-2024-january-11-19733-2027?utm_source=stocktwits.com&utm_medium=referral&utm_campaign=filing

User Image tickeron Posted - 01/09/24

Does this make you nervous? $GNFT MACD Histogram turned negative on January 8, 2024. View odds of downtrend. https://srnk.us/go/4964329

User Image Stocks4thought Posted - 4 months ago

$GNFT Rock and roll$

User Image STCKPRO Posted - 12/16/23

$GNFT NEW ARTICLE : Genfit (GNFTF) Receives a Buy from Kepler Capital https://www.stck.pro/news/GNFT/70495233/

User Image Escalation Posted - 12/13/23

$GNFT over $CBAY smells like BO

User Image STCKPRO Posted - 12/11/23

$GNFT NEW ARTICLE : Optimistic Outlook for Genfit: Justine Telliez Raises Target Price Amid Positive Drug Developments https://www.stck.pro/news/GNFT/69974765/

Analyst Ratings
HC Wainwright & Co. Buy Apr 5, 24
HC Wainwright & Co. Buy Dec 8, 23
HC Wainwright & Co. Buy Sep 21, 23
HC Wainwright & Co. Buy Jul 3, 23
HC Wainwright & Co. Buy Jun 1, 23
HC Wainwright & Co. Buy May 24, 23
HC Wainwright & Co. Buy Apr 17, 23
SVB Leerink Outperform Apr 11, 22
HC Wainwright & Co. Buy Dec 20, 21